Law360, New York (September 02, 2009) -- Pfizer Inc. will pay $2.3 billion and one of its subsidiaries will plead guilty to a criminal charge to settle claims that the drug giant improperly marketed the discontinued anti-inflammatory drug Bextra and three other medicines, federal regulators announced Wednesday, marking the largest such settlement on record.
Pfizer first reported that it had reached the settlement in principle in a January filing with the U.S. Securities and Exchange Commission....
